YOU ARE HERE:
References
| Last updated: 27.10.05 |
Arnold GF et al. Neutralization of diverse HIV-1 primary isolates elicited by gp41 ELDKWA-displaying human rhinoviruses selected from combinatorial libraries. AIDS Vaccine 04, Lausanne, abstract 96, 2004.
Arthur LO et al. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. AIDS Res Hum Retroviruses 14: S311-S319, 1998.
Barnett SW et al. Next general enhanced DNA and protein vaccine approaches stimulate potent immune responses against HIV antigens. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 22, 2001.
Barouch DH et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415: 335-339, 2002.
Barouch D et al. Immunogenicity of heterologous prime-boost vaccine regimens involving adenovirus serotypes 11 and 35. AIDS Vaccine 04, Lausanne, abstract 14, 2004.
Belshe RB et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. Journal of Infectious Diseases 183(9):1343- 1352, 2001.
Berman, PW et al. Development of bivalent rgp120 vaccines to prevent HIV Type 1 infection. AIDS Research and Human Retroviruses, 14(S3): S-277-289, 1998.
Betts M et al. Lack of protection from HIV-1 infection by Gag-specific CD4+ and CD8+ T-cell responses induced by a recombinant HIV canarypox vaccine vector (vCP205). AIDS Vaccine 04, Lausanne, abstract 86, 2004.
Boyer JD et al. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. Journal of Infectious Diseases 181(2): 476-483, 2000.
Bures R et al. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Research and Human Retroviruses 16(18): 2019-2035, 2000.
Chantratita W et al. Delayed progression to AIDS in volunteers treated with long-term HIV-1 Immunogen (REMUNE®) therapy in Thailand. HIV Med 5: 317-325, 2004.
Daniel MD et al. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258: 1938-1941.
Desrosiers R et al. Avoidance of antibody recognition by SIV- and HIV-encoded envelope proteins. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract L1, 2001.
Ferrantelli F et al. Twenty-four hour post-exposure immunotherapy with neutralizing monoclonal antibodies protected neonatal macaques from SHIV-induced acute disease. AIDS Vaccine 04, Lausanne, abstract 58, 2004.
Francis, DP et al. Advancing AIDSVAX to Phase 3. Safety, Immunogenicity, and plans for Phase 3. AIDS Research and Human Retroviruses, 14(S3): S-321-323, 1998.
Guimaraes-Walker A et al. Priming with a candidate HIV-1 clade A DNA vaccine followed by booster with HIV-1 clade A MVA vaccine in volunteers at low risk of HIV infection. AIDS Vaccine 04, Lausanne, abstract 55, 2004.
Habel A et al. DNA vaccine protection against challenge with simian/human immunodeficiency virus 89.6 in rhesus macaques. Developments in Biologicals (Basel) 104: 101-105, 2000.
Hirsch, V et al. Attenuated vaccinia virus as a vector for an AIDS vaccine. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, http://www.retroconference.org, 1999.
Hu S-L et al. Immunogenicity and protective efficacy of recombinant vaccines expressing SIV Gag/Pol and HIV-1 Env proteins with mutant N-linked glycosylation sites. AIDS Vaccine 04, Lausanne, abstract 100, 2004.
Isaacs R. Impact of pre-existing immunity on the immunogenicity of Ad5-based vaccines. AIDS Vaccine 04, Lausanne, abstract 69, 2004.
Jacko W et al. Safety and immunogenicity of DNA and MVA HIVA vaccines in phase I HIV-1 vaccine trials in Nairobi, Kenya. AIDS Vaccine 04, Lausanne, abstract 56, 2004.
Johnson, PR et al. Adeno-associated virus as a live viral vaccine vector for AIDS. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, http://www.retroconference.org, 1999.
Johnston, R et al. Immunizing against SIV using alphavirus vectors. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, http://www.retroconference.org, 1999.
Kelleher A et al. Safety and preliminary immunogenicity of a B-subtype DNA prime/recombinant fowlpox virus boost prophylactic HIV vaccine candidate: results of a phase I/IIA trial. 16th Annual Conference of the Australasian Society for HIV Medicine, Canberra, 2004.
Kent SJ et al. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. Journal of Virology 72: 10180-10188, 1998.
Kent S et al. A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques. Vaccine 18(21): 2250-2256, 2000.
Kent SJ et al. Expanded immunogenicity and efficacy of single DNA and fowlpoxvirus prime/boost vaccines each expressing up to 5 shared genes of HIV-1 subtype A/E or SHIV in macaques. AIDS Vaccine 04, Lausanne, abstract 61, 2004.
Kran A-MB et al. HLA-and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc 4x). AIDS 18: 1875-1883, 2004.
LaCasse RA et al. Fusion-competent vaccines: broad neutralisation of primary isolates of HIV. Science 283 (5400): 357-362, 1999.
Liao H-X et al. Modifications to artificial group M consensus envelopes can augment envelope immunogenicity and breadth of induced neutralization of HIV-1 primary isolates. AIDS Vaccine 04, Lausanne, abstract 97, 2004.
Lorin C et al. Measles vaccine as a potential vector for AIDS vaccination. AIDS Vaccine 04, Lausanne, abstract 13, 2004.
Kran A-MB et al. HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). AIDS 18: 1575-1883, 2004.
MacGregor RR et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. Journal of Infectious Diseases 178(1): 92-100, 1998.
McMichael A. Clinical studies with a recombinant MVA HIV vaccine. AIDS Vaccine 04, Lausanne, Abstract 72.
Okuda K et al. Various routes of application of new type HIV-1 DNA vaccine induces strong antigen-specific immune responses. Thirteenth International AIDS Conference, Durban, abstract A481, 2000.
Otten G et al. Delivery technologies enhance plasmid DNA vaccination in a rhesus macaque maodel for HIV-encoded envelope proteins. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 27, 2001.
Pinto LA et al. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS 13: 2003-2012, 1999.
Schnell MJ et al. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci U S A 97: 3544-3549, 2000.
Shiver JW et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335, 2002.
Smith D et al. Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline. HIV Med 2: 272-275, 2001.
Staprans SI et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. PNAS 101:13025-13031, 2004.
Tangy F. Viral vectors overview. AIDS Vaccine 04, Lausanne, abstract 74, 2004.
Tartaglia, J et al. Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Research and Human Retroviruses, 14(S3): S-291-298, 1998.
Tellez I et al. HIV-specific T cell responses in seronegative volunteers immunized with an HIV-1 gag-pol DNA vaccine. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 656, 2000.
van Harmelen J et al. In vivo cross-protection using an HIV-1 subtype B and subtype C DNA vaccine and a recombinant vaccinia virus challenge model in mice. Thirteenth International AIDS Conference, Durban, abstract A1290, 2000.
Xin K-Q et al. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Human Gene Therapy 12(9): 1047-1061, 2001.
Xu L et al. DNA shuffling creates HIV-1 gp120 variants that induce broadly neutralizing antibodies in rabbits. AIDS Vaccine 04, Lausanne, abstract 95, 2004.
Zhang H et al. Human immunodeficiency virus type 1 Gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding Gag. Journal of Virology 78: 10249-10257, 2004
Zuniga A et al. Live attenuated measles virus: a candidate vector for HIV vaccine. AIDS Vaccine 04, Lausanne, abstract 12, 2004.